Adeno-associated virus-based expression vectors

Optimized AAV expression vectors using CRISPR/Cas9 effectively target and correct the CYP21A2 gene in adrenal cells, addressing the limitations of current treatments for congenital adrenal hyperplasia by achieving high transgene expression and minimizing side effects.

WO2025029171A1PCT designated stage expired Publication Date: 2025-02-06OBSHCHESTVO S OGRANICHENNOJ OTVETSTVENNOSTYU GENETICHESKIE TEKHNOLOGII (OOO GENETICHESKIE TEKHNOLOGII)
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/RU2024/050143
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-29
Filing Date
2024-07-01
Publication Date
2025-02-06

AI Technical Summary

Technical Problem

Current treatments for congenital adrenal cortex dysfunction, such as congenital adrenal hyperplasia, rely on glucocorticoids which can have adverse effects like growth inhibition and require frequent dosing, and existing gene editing technologies like CRISPR/Cas9 are not specifically optimized for this condition.

Method used

Development of optimized adeno-associated virus (AAV) expression vectors, including PAAV-NEFCAS9 and AAV-HCYP21A2, that utilize CRISPR/Cas9 with low immunogenicity and high specificity to target and correct the CYP21A2 gene, enabling efficient gene editing in adrenal cells with minimal off-target effects.

Benefits of technology

These vectors achieve high transgene expression levels, stable integration, and effective correction of the CYP21A2 gene, potentially restoring normal steroidogenesis with reduced side effects and improved treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000013_0001
    Figure IMGF000013_0001
  • Figure IMGF000016_0001
    Figure IMGF000016_0001
  • Figure IMGF000018_0001
    Figure IMGF000018_0001
Patent Text Reader

Abstract

The group of inventions relates to biotechnology and medicine, and more particularly to expression vectors for producing proteins in mammalian cells, a combination of said expression vectors for treating congenital adrenal hyperplasia, as well as a method envisaging the use of said combination, and a set of expression vectors based on an adeno-associated virus (AAV) virion, for use in medicine, and in particular for treating congenital adrenal hyperplasia.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Expression vectors based on adeno-associated virus

[0002] Field of technology to which the invention relates

[0003] The group of inventions relates to biotechnology and medicine, namely to expression vectors for producing proteins in mammalian cells, their combinations for the treatment of congenital dysfunction of the adrenal cortex, as well as to a method involving the use of said combination and a set of expression vectors based on the viral particle of the adeno-associated virus (AAV), which can find application in medicine, in particular for the treatment of congenital dysfunction of the adrenal cortex.

[0004] State of the art

[0005] Congenital adrenal hyperplasia (CAH) is a group of disorders associated with a deficiency of cortisol and / or aldosterone (steroid hormones). The deficiency is caused by genetic mutations in the enzyme involved in the formation of cortisol and aldosterone from cholesterol. The enzyme may be completely absent or produced in insufficient quantities. The most well-known forms of CAH are 21-hydroxylase deficiency and 11-beta-hydroxylase deficiency. 21-hydroxylase deficiency (CYP21A2) can cause decreased cortisol / aldosterone levels and increased androgen concentrations. Excess androgens lead to male-pattern changes in the external genitalia in newborn girls (called virilization). Boys with this genetic defect do not show characteristic clinical symptoms at birth, but are susceptible to early puberty due to excess androgens.People with this genetic defect may experience early facial and body hair growth, acne, and menstrual irregularities. The condition can also lead to infertility. 21-hydroxylase deficiency is caused by mutations in the CYP21A2 gene. Patients may have a classic (more severe) or non-classical form of the disease. Classic deficiency may include:

[0006] 1. Salt-wasting adrenal insufficiency is a severe form of the disease caused by extremely low enzyme activity, which leads to a deficiency of cortisol and aldosterone. Aldosterone deficiency leads to a pathological decrease in sodium (hyponatremia) and an increase in potassium (hyperkalemia) in the body. If left untreated, it can lead to acute adrenal insufficiency and shock.

[0007] 2. Simple - the enzyme activity is reduced, but remains sufficient to maintain aldosterone synthesis at a normal or slightly reduced level.

[0008] The non-classical variant of the pathology is the most common, causing a less severe form of the disease. It occurs in approximately one in 1,500 newborns in the Caucasian population. In this variant, enzyme activity is approximately 50%, which avoids critical sodium deficiency and severe consequences. Androgen levels are slightly elevated.

[0009] Treatment of congenital adrenal cortex dysfunction in children according to the Federal Clinical Guidelines [Federal Clinical Guidelines - Protocols for the Management of Patients with Congenital Adrenal Cortex Dysfunction in Children, Problems of Endocrinology, 2014;60(2): 42-50] is carried out using conservative methods.

[0010] Thus, the drug of choice for treating children with CAH is oral hydrocortisone (1+++). The use of hydrocortisone syrup and extended-release glucocorticoids in children during the period of active growth is not indicated (1++). All children with the salt-wasting form of CAH are prescribed fludrocortisone, and infants should receive additional dietary salt (1++).

[0011] The main principle of treatment for all forms of CAH is the administration of glucocorticoids, which compensate for the cortisol deficiency and thereby suppress excessive secretion of adrenocorticotropic hormone (ACTH). This reduces the adrenal gland's production of those steroids that are synthesized in excess due to the specific enzymatic block.

[0012] There are various medications with glucocorticoid activity: prednisolone, cortisone, dexamethasone. Extended-release synthetic glucocorticoids (prednisolone, dexamethasone) negatively affect growth. For children with open growth plates, especially younger children, oral hydrocortisone analogues are considered the most optimal medications. The initial daily dose of hydrocortisone required to suppress ACTH secretion in children under one year of age can reach 20 mg / m. 2 On average, the daily dose of hydrocortisone for children over 1 year old should be 10-15 mg / m 2 The drug is given 3 times a day in equal doses (at 7:00, 15:00 and 22:00).

[0013] In the salt-wasting form of CAH, therapy with the mineralocorticoid fludrocortisone is required, prescribed at a dose of 0.05-0.15 mg per day (1-2 times daily). In infants, the mineralocorticoid requirement is higher and can reach 0.3 mg per day; the dose can be divided into 3 doses. Children without clinical manifestations of salt-wasting syndrome may have subclinical mineralocorticoid deficiency, characterized by elevated renin levels. In such cases, fludrocortisone therapy is also indicated.

[0014] Genetic therapy may be an alternative to conservative treatment.

[0015] Adeno-associated virus (AAV) holds promise for use in human gene therapy. AAV can effectively infect both dividing and non-dividing human cells, integrating its genome into a single chromosomal site within the host cell's genome. The presence of AAV in the human body is not associated with any disease.

[0016] Known AAV vectors for gene therapy address the challenge of creating tools and methods that enable stable, high-volume, and large-scale production of AAV vectors in insect cells [RU2457252 C2, July 27, 2012]. Thus, these known vectors are universal, meaning they are suitable for use regardless of the specific disease. However, specific problems often require specific solutions, so an optimal design must be developed for each task.

[0017] An AAV vector containing gRNA and Cas9 is known in the art, where the Cas9 molecule is either active or inactive S. pyogenes Cas9. The vector is used for antitumor therapy, including adrenal cancer [RU2019133280 A, April 22, 2021]. However, this solution is not intended for the treatment of congenital adrenal cortex dysfunction. An AAV vector containing Cas9, NLS, and HA is also known [KR1020150056539 A, May 26, 2015].

[0018] In addition, an AAV vector containing Cas9, SV40 NLS, HA [US20210054405 A, 02 / 25 / 2021] and an AAV vector, including serotype 2, containing guide RNA, ITR, intended for adrenal therapy [W02020082047 A1, 04 / 23 / 2020] are known. However, none of these vectors solves the problem of treating congenital adrenal cortex dysfunction.

[0019] The use of vectors for targeting the CYP21A2 gene in the human genome containing guide RNA and Streptococcus pyogenes Cas9, NLS, and the eukaryotic elongation factor EF1 alpha is known [Neville E. Sanjana, Ophir Shalem, and Feng Zhang, Improved vectors and genome-wide libraries for CRISPR screening, Nat Methods. 2014 Aug; 11(8): 783–784]. However, this solution concerns a lentiviral vector, which is not suitable for the treatment of congenital adrenal cortex dysfunction.

[0020] A system of AAV vectors (combination) is known, where one of the vectors carries a guide RNA, and the second C AS. In this case, the vectors also contain an ITR, promoters and a tag, and the CRISPR enzyme contains a C-terminal NLS and an N-terminal NLS.34. The vectors are intended for use in a composition for the production of a therapeutic drug for ex vivo gene or genome editing, or for modifying a mammalian organism by manipulating the target sequence in a genomic locus of interest. Vectors can also be used in a method for treating or suppressing a condition in a cell containing a defective nucleotide element, or a trinucleotide repeat, or another repetitive nucleotide element, or a nucleotide expansion [RU2016128069 A, 17.01.2018]. This solution is the closest to the claimed solution, however, it concerns a lentiviral vector, which is not suitable for the treatment of congenital adrenal cortex dysfunction.

[0021] The technical problem solved by the claimed group of inventions is the creation of genetic constructs containing optimized sequences, including S. pyogenes Cas9, providing a high level of transgene expression, which can be used for the treatment of congenital adrenal cortex dysfunction. Disclosure of the invention

[0022] When implementing the claimed group of inventions, the following technical results are achieved:

[0023] 1. low immunogenicity;

[0024] 2. fairly easy to produce;

[0025] 3. degree of non-specific cutting 0.01%;

[0026] 4. broad tropism to different tissues;

[0027] 5. high level of transgene expression: the number of viral genomes per cell is from 1 to 100, expression is from 10' 4 up to 10' 1 relative to the control gene GAPDH.

[0028] Technical results are achieved through the following.

[0029] One of the group's inventions is the pAAV-nEFCas9 expression vector.

[0030] This vector represents viral particles of adeno-associated viruses, capsid proteins of natural serotypes (1, 2, 3, 4, 5, 7, 8, 9hul4, rhlO and others) or serotypes obtained by synthetic biology methods (DJ / 8, DJ, aps32 and others).

[0031] The particles are packaged with a single-stranded DNA molecule containing AAV virus internal terminal repeats (ITRs) at their ends, preferably serotype 2, as the genome. These AAV ITRs have been well studied, and their use produces a stable, expected effect. However, other AAV ITRs may be used, as there is no prior art information indicating that ITRs from other AAV serotypes will produce an incorrect result. The AAV ITRs contain a sequential promoter of the first eukaryotic elongation factor, EF1 alpha. The selection of this particular promoter was the result of a series of experiments showing that it yields a high level of transgene expression in the vector construct of the present invention. Furthermore, it is eukaryotic, not viral, and therefore will not be methylated or inhibited, which is an additional advantage of the present invention. Furthermore, the promoter is constitutive, i.e.It will work in all cell types. Following the mentioned promoter is a histidine tag sequence (HA (human influenza hemagglutinin) epitopetag), which serves for easy identification of the transgene by Western blotting, cytometry, and immunohistochemistry. The tag is followed by a 5'-SV40 NLS nuclear localization signal. The advantage of this nuclear signal is its small size and, as has been shown, a high degree of protein transfer into the nucleus. Next comes the codon-optimized sequence of the Cas9 gene of Streptococcus pyogenes. The Cas9 effector is relatively small in size and is capable of introducing a double-strand break into the target locus in the genome. The CRISPR / Cas9-based genome editing system is easy to use and design, the degree of non-specific cutting is 0.01%, with the need to select a specific guide RNA that is easy to synthesize. This is the main challenge, the solution to which depends on achieving the specified specificity.An optimal guide RNA was developed that maximizes the benefits of the CRISPR / Cas9-based genome editing system. An incorrectly selected guide RNA will reduce the benefits of this system. Codon optimization (SEQ ID NO: 5) was performed to more efficiently synthesize the bacterial protein in human cells, which also achieved the aforementioned effects. However, other codon optimization options are possible, so the variant used in this development is demonstrative and demonstrates the fundamental feasibility of achieving the effects of the invention by optimizing this sequence. The codon-optimized sequence is followed by another intracellular localization signal, the 3'-SV40 NLS, located in the nucleus. A synthetic polyA signal was used as a transcription terminator.

[0032] Another invention of the group is the AAV-hCYP21A2 expression vector.

[0033] The particles contain a single-stranded DNA molecule packaged as a genome, terminated by AAV internal terminal repeats (ITRs), preferably serotype 2. These AAV ITRs have been well studied, and their use yields the expected, stable effect. However, other AAV ITRs may be used, as there is no prior art data indicating that ITRs from other AAV serotypes will produce an incorrect result. The eukaryotic polymerase III promoter, U6, is located sequentially within the vector. This U6 promoter has demonstrated high levels of transgene transcription in the vector construct according to the invention. It is eukaryotic, not viral, and therefore will not be inhibited in human cells. Its relatively small size allows for packaging of the guide RNA transcription cassette within the AAV genome. The U6 promoter is followed by a guide RNA sequence in crRNA format.This is a unique 20-nucleotide sequence complementary to the target locus, linked to a trackRNA sequence (scaffold). Following the guide RNA expression cassette is a region of homology with the AAVS1 locus of the human genome (the left homology arm). This locus was chosen because numerous experiments have shown that integration into it does not affect the functioning of the rest of the genome, ensuring safe integration. Furthermore, the transgene integrated into this locus is efficiently transcribed in any cell type. The transgene expression cassette contains the EFS-NS promoter. This promoter is responsible for high levels of transgene expression. It is eukaryotic, not viral, and therefore will not be methylated or inhibited. It is also a constitutive promoter, meaning it functions in all cell types. It controls the codon-optimized protein-coding sequence of the hCYP21A2 gene.Codon optimization increased gene translation efficiency; optimization was performed relative to the corresponding reference sequence NG_007941.3. The human P-globin polyadenylation signal (PAS) was used as the transcription terminator. Following the PAS signal is a region of homology with the AAVS1 locus of the human genome (the right homology arm).

[0034] Another invention of the group is a combination of pAAV-nEFCas9 and AAV-hCYP21A2 expression vectors and a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient in the combination comprises a buffer and / or saline solution. Non-limiting examples of buffers that can be used in the present solution include: phosphate, phosphate-citrate, Tris, carbonate, bicarbonate, borate, acetate, glycerol, phosphate-glycerol, Tris-glycerol, and citrate buffers. Another invention is a method for treating congenital adrenal cortex dysfunction, comprising administering an effective amount of a combination of the said vectors to a mammal.

[0035] The group's invention also includes a set of vectors, wherein one of the expression vectors is a pAAV-nEFCas9 vector, and the second expression vector is an AAV-hCYP21A2 vector. The set may additionally contain a buffer and / or a saline solution. Non-limiting examples of buffers that can be used in the present solution include: phosphate, phosphate-citrate, Tris-buffer, carbonate, bicarbonate, borate, acetate, glycerol, phosphate-glycerol, Tris-glycerol, and citrate buffer.

[0036] Brief description of the drawings

[0037] The invention is explained by the following illustrative material.

[0038] Fig. 1 - Schematic diagram of the iodixanol solution layers in a centrifuge cup. The 40% fraction is collected after centrifugation of the QuickSeal tubes. First, a separate needle is used to puncture the very top of the tube to allow air to enter. The desired fraction is then collected using a second needle and syringe, with the needle opening facing upward and the tip positioned horizontally approximately 2 mm below the 40-60% interphase. This method aspirates 40% of the gradient without disturbing the interphase of the 25% layer.

[0039] Fig. 2 - AAV-hCYP21A2 map.

[0040] Fig. 3 - pAAV-nEFCas9 map.

[0041] Fig. 4 - diagram of the test for restoration of steroidogenesis upon integration of a normal copy of the CYP21 gene into the genome of an organism mutant for this gene.

[0042] Fig. 5 - Photograph of a sample after immunofluorescence staining of EGFP in the adrenal glands of CYP21A1- / - mice 2 weeks after vector injection.

[0043] Fig. 6 - Results of studies confirming the integration of the donor into the target Rosa26 locus in the mouse adrenal gland genome. A) Agarose gel electrophoresis of target amplicons ("C+" positive control, "C-" negative control). B) Sanger sequencing chromatograms of amplicons from (A). Fig. 7 - Diagrams showing the viral load and transgene expression level in target organs.

[0044] Fig. 8 A-D - graphs demonstrating the increase in body weight and the level of steroid hormones in experimental animals.

[0045] Fig. 9 - Representative photographs of uninjected CYP21A1+ / + mice (control) and CYP21A1- / - mice injected with AAVDJ-CYP21A1-01, AAVDJ-SpCas9 + AAVDJ-CYP21A1-01, or PBS, 16 weeks after vector injection.

[0046] Implementation of the invention

[0047] One of the group's inventions is an expression vector based on adeno-associated viruses, capsid proteins of natural serotypes (1,

[0048] 2, 3, 4, 5, 7, 8, 9hul4, rhlO and others) or serotypes obtained by synthetic biology methods (DJ / 8, DJ, anc32 and others). A single-stranded DNA molecule is packed into particles as a genome, at the ends of which ITRs (internal terminal repeats) of the serotype 2 virus are located, inside there are sequentially located the promoter of the first eukaryotic elongation factor EF1 alpha, then the sequence of the histidine tag (HA (humanin fluenza hemagglutinin) epitopetag), after which there is a signal for intracellular localization in the nucleus 5'-SV40 NLS, then the codon-optimized sequence of the Cas9 gene of Streptococcus pyogenes. Then there is another signal for intracellular localization in the nucleus 3'-SV40 NLS. A synthetic polyA signal is used as a transcription terminator. An example of the embodiment of the invention can be SEQ ID NO: 1.

[0049] Another invention of the group is an expression vector based on adeno-associated viruses, capsid proteins of natural serotypes (1, 2,

[0050] 3, 4, 5, 7, 8, 9hul4, rhlO and others) or serotypes obtained by synthetic biology methods (DJ / 8, DJ, aps32 and others).

[0051] A single-stranded DNA molecule is packaged into particles as a genome, at the ends of which ITRs (internal terminal repeats) of the serotype 2 virus are located, inside there are sequentially located: the eukaryotic U6 polymerase III promoter, the guide RNA sequence in the crRNA format (a unique sequence of 20 nucleotides, complementary to the target locus, linked with the trackRNA sequence (scaffold)), behind the guide RNA expression cassette there is a region of homology with the locus of the human genome AAVS1 (left homologous arm), the expression cassette of the transgene, including the EFS-NS promoter, under the control of which the protein-coding sequence of the hCYP21A2 gene, corresponding to the reference sequence NG_007941.3, is located. The polyA signal of the human P-globin gene (human P-globin polyadenylation signal) was used as a transcription terminator. Following the polyA signal is a region of homology with the human genome locus AAVS1 (right homologous arm).An example of implementation is SEQ ID NO: 2.

[0052] SEQ ID NO: 3 is the wild-type CYP21A2 gene sequence NG_007941.3.

[0053] SEQ ID NO: 4 is an optimized sequence variant of SEQ ID NO: 3.

[0054] SEQ ID NO: 5 is the codon optimized sequence of the Cas9 gene from Streptococcus pyogenes.

[0055] The invention also relates to a method for treating congenital adrenal cortex dysfunction, comprising administering to a mammal a combination of said vectors in an effective amount.

[0056] As used herein, the term "therapeutically effective amount" refers to the quantitative content of a vector combination that produces a therapeutic effect on CAH, or alleviates, improves, or eliminates one or more symptoms of the disease. The term "therapeutically effective amount" refers to the quantitative content of a vector combination sufficient to provide the desired therapeutic effect. Therefore, when preparing the medicament according to the present invention in dosage units, the effective dosage is taken into account. The dosage of the agent in patients can be adjusted depending on the therapeutic efficacy and bioavailability of the active components in the body, the rate of their metabolism and elimination from the body, as well as age, gender, and stage of the disease.

[0057] The recommended dose for therapy is a single dose of 2 x 10 л 11 to 2 x 10 л14 viral genomes per 1 kg body weight, corresponding to 2 ml / kg body weight, administered as intravenous infusion after dilution with buffer or 9 mg / ml (0.9%) sodium chloride solution for injection.

[0058] The recommended administration regimen is a single intravenous infusion.

[0059] Since genetic therapy for congenital adrenal cortex dysfunction is mediated by mutations in the hCYP21A2 gene, treatment can be achieved by exogenous expression of the hCYP21A2 gene from the genome of a vector that has infected adrenal cells and is expressed in nuclei as episomal DNA. A double-strand break is introduced into the genome of infected cells through the expression of a guide RNA specific to the AAVS1 locus sequence, adeno-associated virus integration site 1, PPP1R12C protein phosphatase 1 regulatory subunit 12C, NC_000019.10, and through the expression of the Cas9 protein, which is capable of introducing a double-strand break into DNA at the site of homologous binding of the guide RNA to the target. Integration occurs due to the presence of regions homologous to the AAVS1 locus in the AAV-hCYP21A2 vector. As a result of breakpoint introduction, homologous repair, and transgene expression, hCYP21A2 gene expression is realized and normal steroidogenesis in the adrenal cortex is restored.

[0060] A more detailed description of the claimed invention is provided below. The present invention is subject to various changes and modifications that would be apparent to those skilled in the art based on this description. Such changes do not limit the scope of the claims.

[0061] To produce viral particles, plasmid constructs carrying the nucleotide sequences of the vector genomes, as well as the replication and selection sequences of these plasmids in bacterial systems, were used. These plasmids were produced using molecular cloning and gene synthesis.

[0062] Plasmids carrying the capsid genes of the viral part of AAV and helper genes were also used.

[0063] Viral vectors were assembled in adherent or suspension cell / dedicated cell line systems based on HEK293 cells.

[0064] EXAMPLE 1

[0065] Plasmid Isolation and Purification: E. coli cells stored at -80°C were thawed onto solid medium. Frozen cells were added to 400 µl of liquid LB medium (on the tip of a pipette tip), resuspended, and transferred to solid LB medium containing carbenicillin at a concentration of 100 mg / l.

[0066] To obtain a suspension culture, 100 ml of LB medium was added to a 250 ml flask. One colony was added to the tip of a spike, and the E. coli were incubated for 16-20 hours at 37°C in a thermostatically controlled shaker with constant stirring at 170 rpm.

[0067] Plasmid DNA was then isolated using the Plasmid Midiprep 2.0 kit (Eurogen) according to the manufacturer's protocol. The number of columns was calculated at a rate of 1 column per 1 g of cell pellet (column capacity: 500 μg DNA). Each column was eluted twice with 4 ml of water.

[0068] After isolation, the plasmid concentration was measured and restriction analysis was performed using restriction enzymes according to Table 1.

[0069] For each sample, the following reactions were carried out: restriction with each of the restriction enzymes listed in Table 1 separately, for all restriction enzymes in one test tube, K-reaction without restriction enzymes.

[0070] The following mixture was prepared: lOXBuf - 2.5 µl; restriction enzymes - 0.5 µl each; plasmid DNA - 600 ig; water up to 25 µl.

[0071] Incubated for 1 hour at 37°C and visualized in 1% agarose gel.

[0072] Table 1. The number of viral genomes per cell ranges from 1 to 100.

[0073] Expression - from 10' 4 up to 10 1 relative to the control gene GAPDH.

[0074] EXAMPLE 2

[0075] Preparation of HEK293 cell culture

[0076] All volumes of media, solutions, etc. are given based on one 15 cm culture dish.

[0077] Media for cell mass expansion (GM) and transfection (TM) were prepared. To prepare GM, 50 ml of FBS (Gibco), 5 ml of x100 GlutaMax (Gibco), and 500 μl of the antibiotic x1000 Gentamicin (PanEco) were added to 450 ml of DMEM medium containing 4.5 g / L glucose. To prepare TM, 10 ml of FBS (Gibco), 5 ml of x100 GlutaMax (Gibco), and 500 μl of the antibiotic x1000 Gentamicin (PanEco) were added to 490 ml of DMEM medium containing 4.5 g / L glucose.

[0078] Versene and 0.25% Trypsin solutions were aliquoted at 50 ml each. An aliquot of the Versene solution was stored at room temperature, and aliquots of the 0.25% Trypsin solution were stored at -20°C. Before working with the cells, the trypsin solution was brought to room temperature, and the GM / TM medium was transferred to a water bath at +37°C.

[0079] The cell line was passaged. The cell line passage did not exceed 12.

[0080] The HEK293 cell culture was thawed. Before thawing, the cryovials were heated with 25 ml of GM in a water bath at 37°C.

[0081] The cryovial was placed in a water bath at 37°C until completely thawed. Immediately after thawing, the entire contents of the cryovial were transferred to a 15 ml tube, and 10 ml of preheated GM was added. The mixture was centrifuged at 230g for 3 minutes. The supernatant was discarded, the cell pellet was resuspended in 1 ml of GM, transferred to a T75 cell flask, and 14 ml of GM was added. The flask was incubated in a CO2 incubator at 5% CO2 and 37°C until 70% cell confluency was reached.

[0082] The HEK293 cell culture was frozen.

[0083] Before freezing the cell bank, a test for the absence of mycoplasma in the cells was performed according to the MycoReport protocol (Eurogen).

[0084] All medium was removed from the dish, 5 ml of Versene solution was added, and the mixture was incubated for 1 minute in a laminar flow hood. The Versene solution was removed, 3 ml of 0.25% Trypsin solution was added, and the mixture was incubated for 3 minutes in a laminar flow hood. 3 ml of GM was added, the cells were carefully and thoroughly resuspended, and 10 µl of the cell suspension was removed into a 0.2 ml tube. The remaining cells were transferred to a 15 ml tube.

[0085] The number of cells was counted and their viability was determined using a TC-20 automated cell counter (BioRad): 10 μl of a 0.4% trypan blue solution was added to 10 μl of a well-mixed cell suspension and mixed; 10 μl of the resulting suspension was applied to a cell counting slide, and measurements were taken.

[0086] Cells in a 15 ml tube were centrifuged at 230 g for 3 min.

[0087] We calculated the required number of cryovials so that each cryovial contained 5 million cells per 1 ml of freezing solution. We labeled each cryovial: line name, cell count, date, and operator.

[0088] We prepared a solution for freezing: for one cryovial we need 700 µl of FBS (Gibco), 200 µl of DMEM with a glucose content of 4.5 g / l (PanEco), 100 µl of DMSO (PanEco).

[0089] The cell pellet was resuspended from a 15-ml tube in freezing medium centrifuged at 230 g for 3 min, and 1 ml was aliquoted into cryovials. The cryovials were incubated for 1 day in a kelvinator at -80°C, then transferred to liquid nitrogen at -196°C.

[0090] Passaging of HEK293 cell culture was carried out.

[0091] We removed all the medium and added 5 ml of Versene solution to the dish. We incubated the mixture for 1 minute in a laminar flow hood, and then removed the Versene solution.

[0092] Added 0.25% Trypsin 3 ml per dish, incubated for 3 minutes in a laminar flow hood, added an equal volume of GM medium, carefully resuspended the cells, and transferred to a 15 ml falcon.

[0093] The number of cells was counted and their viability was determined using a TC-20 automated cell counter (BioRad): 10 μl of a 0.4% trypan blue solution was added to 10 μl of a well-mixed cell suspension and mixed; 10 μl of the resulting suspension was applied to a cell counting slide, and measurements were taken.

[0094] 6 million cells were transferred to a new dish, 24 ml of GM was added, and incubated at +37°C, 5% CO2 until the next passage. EXAMPLE 3

[0095] Transfection of HEK293 cell culture.

[0096] The transfection mixture consisted of lactate buffer, linear polyethylene amine, and plasmid DNA.

[0097] Preparation of lactate buffer pH 4 (20 mM sodium lactate, 150 mM sodium chloride)

[0098] To prepare 300 ml of lactate buffer, 1.35 ml of 40% lactic acid was added to 290 ml of 150 mM sodium chloride. The pH was adjusted to 4 using 1N sodium hydroxide solution. The resulting solution was then diluted to 300 ml with 150 mM sodium chloride. The solution was sterilized through a 0.2 µm filter and stored at 4°C.

[0099] Preparation of a solution of polyethyleneimine (1-PEI 25) 5 mg ml

[0100] A 1 g sample of dry linear polyethyleneimine (25 kDa) was dissolved in 190 ml of 0.2 N hydrochloric acid with continuous stirring. The volume was adjusted to 200 ml with hydrochloric acid. The final solution had a pH of 1-2. Aliquots of the solution were stored at -80°C.

[0101] Calculation of the required amount of plasmids and polyethyleneamine (PEI) for transfection

[0102] To transfect 1 15 cm dish, 38 μg of plasmid DNA was used, with a helper:packaging:transfer plasmid copy number ratio of 1:1:1.

[0103] The day before transfection, the cells were reseeded into new dishes at 10 million cells per dish. 24 ml of GM medium was added and the cells were incubated at 37°C, 5% CO2.

[0104] Transfection of HEK293 cell culture. DNA and PEI mixtures were prepared according to Table 2.

[0105] Table 2

[0106] Scheme for preparing a transfection mixture for 40 dishes We added 80 ml of the DNA-1-PEI 25 mixture to 1 liter of TM medium and mixed. All GM medium was removed from the plates. We added 27 ml of the TM-DNA-PEI mixture per plate and mixed gently. The plates were incubated at 37°C, 5% CO2, for 72 hours.

[0107] The transfection efficiency was 95-98%.

[0108] Cell lysis

[0109] A lysis buffer was prepared containing 150 mM NaCl, 50 mM Tris-НСl, 1 mM MgCl2, pH 8.5, 0.5% Triton X-100, and 50 U / ml benzonase. The buffer was sterilized by filtration, not autoclaving. It was stored at +4°C.

[0110] All the medium from the dish was collected in a 25 ml serological pipette, which was used to rinse all the cells from the dish. The cell suspension was transferred to a 50 ml test tube, and the process was repeated for all dishes. The tube containing the cell suspension was centrifuged at 400 g for 5 min, the supernatant was collected as needed, and stored at -80°C. The entire cell pellet from 40 dishes was resuspended in 60 ml of lysis buffer. The dishes were incubated at +37°C for 1 hour.

[0111] Centrifuged at 4000 g for 15 minutes, the clarified supernatant was transferred to a clean tube.

[0112] EXAMPLE 4

[0113] Isolation and purification of AAB

[0114] IM NaCl / PBS-MK buffer and lx PBS-MK buffer were prepared.

[0115] To prepare IM NaCl / PBS-MK buffer, 5.84 g NaCl, 26.3 mg MgCl2 (56.0 mg 6 H2O × MgCl2), and 14.91 mg KCl were dissolved in 1 * PBS to a final volume of 100 ml. The mixture was filtered through 0.22 μm and stored at +4°C.

[0116] To prepare 1x PBS-MK buffer, 26.3 mg MgCl2 (56.0 mg 6 H2O x MgCl2) and 14.91 mg KCl were dissolved in 1 *PBS to a final volume of 100 ml. The solution was filtered through 0.22 μm and stored at +4°C.

[0117] For each ultracentrifugation, only iodixanol solutions prepared in accordance with Table 3 were used.

[0118] Table 3 Calculation for the preparation of iodaxanol solutions for 2 Quick-Seal tubes (39 ml)

[0119] Ул ътрацентирфигуирование

[0120] Layers of iodixanol solutions were added to the centrifuge cup in the order according to Table 4 using a 10 ml syringe and a Zeldiger needle.

[0121] Table 4 The gradient was applied from the top layers so as not to disturb the integrity of the gradient.

[0122] To fill the QuickSeal tube, fill the tube to the top with cell lysate, ensuring no bubbles were present. The tubes were equilibrated with PBS to 0.0005 g on an analytical balance. Centrifugation was performed at 360,000 g (59,000 g for a Beckman Coulter Ti 70 rotor) for 1 hour 30 minutes at 10°C.

[0123] After centrifuging the QuickSeal tubes, we first pierced the very top of the tube with a separate needle to allow air to enter. Then, using a second needle and syringe, we collected the 40% fraction, as shown in Figure 1. The needle opening faces upward, and the tip of the needle is positioned horizontally, approximately 2 mm below the 40-60% interphase. We aspirated 40% of the gradient, avoiding the 25% interphase.

[0124] The collected fraction was transferred to a 50 ml falcon.

[0125] Ultrafiltration. The 40% iodixanol fraction collected after ultracentrifugation was diluted 5-fold with PBS / Pluronic F68 (0.001%) solution and filtered through a filter with a pore size of 0.22 μm. 3 ml of H2O were added to the Amicon Ultra-15 filter, the mixture was centrifuged at 2000 g for 1 min, and then all liquid was completely removed from the tube and from the filter. 3 ml of PBS / Pluronic F68 (0.001%) solution were added to the filter, centrifuged at 2000 g for 1 min, and all liquid was completely removed from the tube and from the filter. 15 ml of the diluted virus was added to the Amicon Ultra-15 filter and centrifuged at 2500 g for 10 minutes in a swing-bucket rotor. The column fluid was discarded and the Amicon Ultra-15 tube was filled until all the vector solution was used. The membrane was then thoroughly washed with the virus solution using a 100-1000 µl pipette. The mixture was centrifuged at 2500 g for 10 minutes.

[0126] After centrifugation, the vector suspension remained in the upper part of the concentrator (volume 500 µl), centrifugation was repeated for 3 minutes.

[0127] After the entire viral particle solution had passed through, the concentrated virus was washed twice with PBS / Pluronic F68 (0.001%) at room temperature. Approximately 500 µl of viral suspension should remain in the filter cassette.

[0128] The membranes were thoroughly washed, after which the virus was aliquoted at 20 µl into 0.2 ml tubes, leaving 5 µl for titer determination.

[0129] AAV-CYP21 - 7.80E+12 viral particles in 1 ml. AAV-Cas9 - 1.93E+12 viral particles in 1 ml.

[0130] EXAMPLE 5

[0131] The restoration of steroidogenesis upon integration of a normal copy of the CYP21 gene into the genome of an organism mutant for this gene was tested according to the scheme in Fig. 4. 5-week-old CD-l-C57Bl / 10SnSlc-H-2awl8 mice were injected into the tail vein with 3*10 л11 viral particles per injection of two recombinant adeno-associated viral vectors, AAB-Cas9 and AAB-Syr, serotype DJ. Animals injected once with PBS (Phosphate-buffered saline) solution served as controls. Mice were maintained under standard conditions for 2, 4, 8, 16, and 30 weeks after injection. After this period, the mice were euthanized, followed by collection of target organs and tissues for analysis. The target organs and tissues included blood, adrenal glands, liver, brain, spleen, gonads, kidneys, thymus, and lungs. Immunofluorescence analysis of adrenal gland sections demonstrated the presence and expression of the injected agents. Figure 5 shows GFP protein staining in the organs of mice that received viral therapy.

[0132] DNA was also isolated from adrenal gland samples from the study animals, and transgene integration into the target Rosa26 genomic locus was analyzed. Primers were selected to amplify the DNA region so that the amplification product would only be obtained if the transgene had successfully integrated into the target locus. A cell line with a previously integrated insert was used as a positive control. Amplification of the test sample yielded three bands of the appropriate length, which were then re-amplified and sequenced using direct Sanger sequencing.

[0133] Sequencing revealed the presence of the desired sequence, thus, it is possible to postulate the presence of transgene integration into the target locus (Fig. 6).

[0134] Viral load and transgene expression levels were also analyzed in the target organs (Fig. 7).

[0135] The therapeutic effect was assessed by analyzing the hormonal status of the animals and body weight gain. Serum collected postmortem from the heart was analyzed by UPLC-MS / MS. The ratio of 11-deoxycorticosterone (DOC, product) to progesterone (Prog, precursor) is shown in Fig. 8. An increase in DOC levels in the virus-infected group indicates increased activity of the 21-OH enzyme (a product of the Cyp21aG gene). SEQUENCE LISTING

[0136] <?xml version="1.0" encoding="UTF-8"?>

[0137] <!DOCTYPE ST26SequenceListing PUBLIC "- / / WIPO / / DTD Sequence Listing 1.3 / / EN" "ST26SequenceListing_Vl_3.dtd">

[0138] <st26sequencelisting dtdversion="Vl_3" filename- 'lxml" softwarename="WIPO Sequence" softwareversion="2.2.0" productiondate="2023-05- 05 ">

[0139] < ApplicantFileReference> 1

[0140] <applicantname languagecode="ru">O6njecTBO with limited liability "Genetic Technologies"< / Аррйсап1№те>

[0141] <applicantnamelatin>Limited Liability Company Genetic

[0142] T echnologies < / ApplicantN ameLatin>

[0143] <inventorname languagecode="ru">Ena3OBa Olga

[0144] Vladimirovna< / 1п\'сп1ог№тс>

[0145] <inventornamelatin>Glazova Olga Vladimirovna< / inventornamelatin>

[0146] <inventiontitle languagecode="ru"> BeKTopbi expression based on adeno-associated BHpyca< / inventiontitle>

[0147] < Sequence Total Quantity > 5

[0148] <sequencedata sequenceidnumber=" 1 ">

[0149] <insdseq>

[0150] < INS D S eq_length > 4774 < / IN S D S eq_leng th >

[0151] <INSDSeq_moltype>DNA< / INSDSeq_moltype>

[0152] <INSDSeq_division>PAT< / INSDSeq_division>

[0153] <INSDSeq_feature-table>

[0154] <insdfeature>

[0155] < INS DFeature_key > source < / IN S DFeature_key >

[0156] <INSDFeature_location>1..4774< / INSDFeature_location>

[0157] <INSDFeature_quals>

[0158] <insdqualifier>

[0159] <INSDQualifier_name>mol_type< / INSDQualifier_name> <INSDQualifier_value>other

[0160] DNA< / INSDQualifier_value>

[0161] < / insdqualifier>

[0162] <insdqualifier id="q3">

[0163] <INSDQualifier_name>organism< / INSDQualifier_name>

[0164] <INSDQualifier_value>synthetic construct< / INSDQualifier_value>< / insdqualifier>

[0165] < / INSDFeature_quals>

[0166] < / insdfeature> < / INSDSeq_feature-table>

[0167] <INSDSeq_sequence>cctgcaggcagctgcgcgctcgctcgctcactgaggccgcccgggcgtcggg cgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcg gcctctagaaaggatctgcgatcgctccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaagttggg gggaggggtcggcaattgaacgggtgcctagagaaggtggcgcggggtaaactgggaaagtgatgtcgtgtactggctcc gcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttcgcaacgggtttgccgccag aacacagctgaagcttcgaatgtcgccgaagaaaaagcgcaaggtcgaagcgtccgacaaaaaatactccatcggtctgga cattggtactaactctgtaggctgggccgttatcacggacgagtacaaagtacctagcaaaaagttcaaagtattggggaatact gacaggcattccataaagaagaatctcataggagcattgctgtttgattccggagagacagcagaagctactcgactcaagag aaccgcacgacgccgatatacacgccgaaaaaaccgaatctgctacctgcaggagatcttctccaatgaaatggctaaggta gacgacagcttctttcatcgacttgaagaatcttttcttgttgaggaggataagaagcacgaacggcaccctattttcggcaatat cgtggatgaggtcgcgtatcatgaaaagtatcccaccatctaccacttgcgaaagaagctggtagatagtaccgacaaggcg gatttgagactcatataccttgcactggcccacatgataaaattcagagggcacttcctcatcgaaggtgatcttaatccagacaacagtgacgtcgataagttgttcattcagctcgtgcagacttacaatcaactgtttgaagaaaatcccataaatgcgtcaggcgtag atgcaaaggctatactctccgcgcgattgtcaaaatcccgacggcttgagaatctcatagcccaacttcccggcgaaaagaaa aacggattgttcgggaaccttattgccttgtcactcggtttgactcctaattttaagagtaatttcgatctggctgaggatgcaaaac tgcagctgagtaaagatacatacgacgacgacctggacaatctcctggcccagattggagaccagtacgccgacctgttcttg gctgccaaaaacctctcagacgctattctcctgtcagacattttgcgcgtgaatactgagattacgaaggcccccctgtctgcct ccatgattaagcgctatgatgagcaccatcaagacttgacccttcttaaagcgctggtacggcagcagctccctgaaaaatata aagaaatcttcttcgaccagtccaaaaatggctacgcgggctacatcgacggaggtgcaagccaggaggagttctataagttt ataaagccgatccttgagaagatggatgggaccgaagaactcctggtgaaacttaacagggaggatctgctgcgaaagcag cgcacatttgataatgggtccattccacatcaaattcatcttggagaattgcacgccattttgagaagacaggaggacttctatcc gtttcttaaggacaatcgggaaaaaatagaaaagatacttacattccgaattccttactatgtcgggcccttggcgcgagggaac tctcggttcgcttggatgactcgaaaaagtgaggagactataactccttggaattttgaagaagtcgtagacaaaggtgcttccgcgcaatcttttatagagagaatgactaatttcgacaaaaacctcccaaacgagaaggttctgccaaagcacagccttctctacga gtattttactgtctataacgaactcactaaggtgaaatacgtaactgaagggatgaggaagcctgcctttttgagtggcgagcag aagaaagcgatagtagatttgctttttaaaaccaaccggaaggtcactgtgaaacaacttaaagaagactacttcaagaagata gagtgtttcgacagcgtagaaatatctggcgtagaggaccgcttcaatgcaagcttgggcacttaccatgacctcctcaagata atcaaagataaagattttcttgataatgaagagaatgaggatatccttgaagacatagtgttgactctcacgttgtttgaggatagg gagatgatagaagagcgcttgaagacctatgctcatctcttcgatgataaagtaatgaagcaactcaagcggagaaggtatact ggttggggtcggctttctaggaaactcatcaacggtattcgggataaacagtccggcaaaactatattggatttccttaagagtg atggcttcgcgaaccgaaactttatgcaacttatacatgatgattcacttacatttaaggaagacattcaaaaagcgcaagtatct ggccagggcgactctctgcacgaacacatagcaaaccttgctggatcccctgcgataaagaaaggtatactgcagacagtaa aagttgtggacgaactcgtcaaggttatgggtaggcataagcccgaaaatatagtgattgaaatggcacgcgagaaccaaact acacaaaaaggtcaaaagaacagcagagaacggatgaaacgaatagaggaggggatcaaggaacttggatcccaaatactgaaagagcaccccgtagaaaatacccagcttcaaaacgagaagctttatctgtactacctgcaaaacggcagagatatgtacg tagaccaggaactggacatcaacagattgtctgattatgatgtagatcacattgtgccgcagagcttcctcaaagatgattccata gataacaaagtactcactcgaagtgacaaaaacagagggaaatccgataatgttcccagtgaggaagtcgtcaagaagatga agaattattggcggcaacttctcaacgcgaaactcatcacccaaagaaaattcgataacctcactaaagctgaacgcggagga ctgtcagagcttgataaagcaggttttatcaaaaggcaactcgtagaaacgagacaaataacaaaacatgtcgctcaaattttgg actctcgcatgaatacaaagtatgatgaaaatgacaagctgattcgcgaggtcaaagtaataacgctcaaaagtaaacttgtctc cgatttccgaaaggactttcagttttacaaagtcagagagataaataattaccaccacgcccatgacgcctacctcaatgctgtg gttggtacggctcttatcaagaaatatccgaagctcgagagcgagtttgtctatggcgactacaaggtttacgatgtcaggaaaa tgatagcgaagtctgagcaagagataggtaaggccacggctaaatactttttctattcaaatatcatgaattttttcaaaaccgaga taacgttggcgaatggcgaaatcaggaaaaggcctcttatagagactaacggagaaacaggcgagattgtctgggataaggg tagggatttcgctactgtgcgaaaggtactgagcatgccccaggttaacattgtcaaaaagactgaggtccaaacgggtggcttttctaggagagtatcctgccaaaacgcaattcagataagctcatagcgagaaaaaaggattgggacccaaagaaatatggc ggcttcgactctccgacggtcgcatatagtgtgctggtggttgccaaagttgaaaagggcaagtctaaaaaactgaaatcagtg aaggagcttctcggaataactattatggagcgcagctcattgaaaagaatccaatcgatttcttggaagcaaaggatataaag aagtcaagaaggacctgatcatcaaacttccaaagtactcactgttcgaacttgagaacggacggaagcggatgcttgcgagt gctggagaacttcaaaaaggtaacgagctcgcccttccatcaaagtacgtaaattttgtacttggcatcacaactatgagaagct caaaggctcccccgaggataatgagcaaaagcagctttcgtggaacaacataaacattaacttaccttgatgaaatcatcgaacaaattcaaacaaatttt aagcgaattctctaaacgagttattcttgcagacgcgaatctggacaaggtgcttagcgcatacaacaagcatcgggataagcc gattcgagaacaagccgaaaatataatccatcttttcactctgacgaacttgggtgcgccggcagccttcaagtacttcgatacc actattgataggaaaacggtatacgagtacaaaagaagtgctggacgctacgcttatccatcagtccatcactgggctctacgag acgaggattgaccttagtcagttgggcggggacagccccaagaagaagaaaaggtggaggccagctaagaattcaataaa agatctttttttcattagatctgtgtgttggtttttgtgtgtgcggccgcaggaacccctagtgatggagttggccactcctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcga gcgagcgcgcagctgcctgcagg< / INSDSeq_sequence>

[0168] < / insdseq>

[0169] < / sequencedata>

[0170] < S equenceD ata sequencelDN umber= " 2 " >

[0171] <insdseq>

[0172] <INSDSeq_length> 3119< / INSDSeq_length>

[0173] <INSDSeq_moltype> DNA< / INSDSeq_moltype>

[0174] <INSDSeq_division> PAT< / INSDSeq_division>

[0175] <INSDSeq_feature-table>

[0176] <insdfeature>

[0177] < INS DFeature_key > source < / IN S DFeature_key >

[0178] <INSDFeature_location> 1..3119< / INSDFeature_location>

[0179] <INSDFeature_quals>

[0180] <insdqualifier>

[0181] <INSDQualifier_name>mol_type< / INSDQualifier_name>

[0182] <INSDQualifier_value>other

[0183] DNA< / INSDQualifier_value>

[0184] < / insdqualifier>

[0185] <insdqualifier id="q5">

[0186] <INSDQualifier_name>organism< / INSDQualifier_name>

[0187] <INSDQualifier_value>synthetic construct< / INSDQualifier_value>

[0188] < / insdqualifier>

[0189] < / INSDFeature_quals>

[0190] < / insdfeature>

[0191] < / INSDSeq_feature-table>

[0192] <INSDSeq_sequence>cctgcaggcagctgcgcgctcgctcgctcactgaggccgcccgggcgtcggg cgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcg gcctctagagagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattagaattaatttga ctgtaaacacaaagatattagtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaa atggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttatatatcttgtggaaaggacgaaacaccgggggc cactagggacaggatgttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgag tcggtgcttttttgaattccaattggacaccccgttctcctgtggattcgggtcacctctcactcctttcatttgggcagctcccctac cccccttacctctctagtctgtgctagctcttccagccccctgtcatggcatcttccaggggtccgagagctcagctagtcttcttc ctccaacccgggcccctatgtccacttcaggacagcatgtttgctgcctccagggatcctgtgtccccgagctgggaccacctt atattcccagggccggttaatgtggctctggttctgggtacttttatctgtcccctccaccccacagtggggccactagggacag gattaagcttgctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaactgggaaagtgatgtc gtgtactggctccgcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttcgcaacg ggtttgccgccagaacacaggaccggtgtctcgccatgctgctcctgggcctgctgctgctgctgcccctgctggctggcgcc cgcctgctgtggaactggtggaagctccggagcctccacctcccgcctcttgccccgggcttcttgcacctgctgcagcccga cctccccatctatctgcttggcctgactcagaaattcgggcccatctacaggctccaccttgggctgcaagatgtggtggtgctg aactccaagaggaccattgaggaagccatggtcaaaaagtgggcagactttgctggcagacctgagccacttacctacaagc tggtgtctaggaactacccggacctgtccttgggagactactccctgctctggaaagcccacaagaagctcacccgctcagcc ctgctgctgggcatccgtgactccatggagccagtggtggagcagctgacccaggagttctgtgagcgcatgagagcccag cccggcacccctgtggccattgaggaggaattctctctcctcacctgcagcatcatctgttacctcaccttcggagacaagatca aggacgacaacttaatgcctgcctattacaaatgtatccaggaggtgttaaaaacctggagccactggtccatccaaattgtgg acgtgattccctttctcaggttcttccccaatccaggtctccggaggctgaagcaggccatagagaagagggatcacatcgtggagatgcagctgaggcagcacaaggagagcctcgtggcaggccagtggagggacatgatggactacatgctccaaggggtg gcgcagccgagcatggaagagggctctggacagctcctggaagggcacgtgcacatggctgcagtggacctcctgatcgg tggcactgagaccacagcaaacaccctctcctgggccgtggtttttttgcttcaccaccctgagattcagcagcgactgcagga ggagctagaccacgaactgggccctggtgcctccagctcccgggtcccctacaaggaccgtgcacggctgcccttgctcaat gccaccatcgccgaggtgctgcgcctgcggcccgttgtgcccttagccttgccccaccgcaccacacggcccagcagcatct ccggctacgacatccctgagggcacagtcatcattccgaacctccaaggcgcccacctggatgagacggtctgggagaggc cacatgagttctggcctgatcgcttcctggagccaggcaagaactccagagctctggccttcggctgcggtgcccgcgtgtgc ctgggcgagccgctggcgcgcctggagctcttcgtggtgctgacccgactgctgcaggccttcacgctgctgccctccgggg acgccctgccctccctgcagcccctgccccactgcagtgtcatcctcaagatgcagcctttccaagtgcggctgcagccccgg gggatgggggcccacagcccgggccagagccagtaaaataaaagatctttattttcattagatctgtgtgttggttttttgtgtgct cgagtgacagaaaagccccatccttaggcctcctccttcctagtctcctgatattgggtctaacccccacctcctgttaggcagattccttatctggtgacacacccccatttcctggagccatctctctccttgccagaacctctaaggtttgcttacgatggagccagag aggatcctgggagggagagcttggcagggggtgggagggaagggggggatgcgtgacctgcccggttctcagtggccac cctgcgctaccctctcccagaacctgagctgctctgacgcggccgtctggtgcgtttcactgatcctggtgcgcggccgcagg aacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacg cccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcagg< / INSDSeq_sequence>

[0193] < / insdseq>

[0194]

[0195] < S equenceD ata sequencelDN umber= " 3 " >

[0196] <insdseq>

[0197] <INSDSeq_length> 10338< / INSDSeq_length>

[0198] <INSDSeq_moltype> DNA< / INSDSeq_moltype>

[0199] <INSDSeq_division> PAT< / INSDSeq_division>

[0200] <INSDSeq_feature-table>

[0201] <insdfeature>

[0202] < INS DFeature_key > source < / IN S DFeature_key >

[0203] <INSDFeature_location>1..10338< / INSDFeature_location>

[0204] <INSDFeature_quals>

[0205] <insdqualifier>

[0206] <INSDQualifier_name>mol_type< / INSDQualifier_name>

[0207] <INSDQualifier_value >genomic DNA < / INSDQualifier_value >

[0208] < / insdqualifier>

[0209] <insdqualifier id="q7">

[0210] <INSDQualifier_name>organism< / INSDQualifier_name>

[0211] <INSDQualifier_value>Homo sapiens< / INSDQualifier_value>

[0212] < / insdqualifier>

[0213] < / INSDFeature_quals>

[0214] < / insdfeature>

[0215] < / INSDSeq_feature-table>

[0216] <INSDSeq_sequence>ggagaacttacaggtcctgccacaatcctaatgcaaggatggagctgcaagttc agtttgggaatcatcagcctggattggtttggtggaagccagggagtggttgagacccccacaggggagctctgaggaagga agttccgaaggagggaacgtaagaaatgaccaggtcagaaccaagggtggtccagaagctaacccttagcttagggacagt ttcacagagaacacgtccatgatgcaagactctgctgagggcctggagcagtgaagactggggcaaggtcaccctctggga agtgaagtcaccagagaccttgcggagcagctttgagagttctctgagtaggaaggtaacagaatgtgaaggacactggaga gaaggccaataggaagcaaacaaaaacaggccaaggaaacccagtacagggggctgcagggcccagggagtgggtccc tcatctctcctccccacgcttggccaggtccccacctcccgggagtgcgtgggctttgaggctgtgcaggaagtgccggtggg gctggtgcagccggccagcgcaaccctgtacgactactacaaccccggtgagcactgcaggacaccctgaaattcaggaga actttggcataggtgccctcctatgggacaatggacaccggggtagtgagggggcagagagccctggggctccctgggact gaggaggcagaatggaggggcctgtgccctaactcctctctgttctccagagcgcagatgttctgtgttttacggggcaccaa gtaagagcagactcttggccaccttgtgttctgctgaagtctgccagtgtgctgagggtgagactgagggcctggggcgggg cagtggaggcgggatggccggggccccccccacactgtctgatgggttccccaacttcagggaagtgccctcgccagcgtcgcgccctggagcggggtctgcaggacgaggatggctacaggatgaagtttgcctgctactacccccgtgtggagtacggtca gtcttcccaccgaggccctggcctgaccctccctcggggaccggccgttttggtctctctgggtgtagcctgctcctcttacagg tcatgcacgcagcctgtttgctctgacaccaacttcctaccctctcagcctcaaagtaactcacctttcccccttctcctcaccccc tcttaggcttccaggttaaggttctccgagaagacagcagagctgctttccgcctctttgagaccaagatcacccaagtcctgca cttcagtatgaagcaaaccggagaggcgggcagggctggggggagacagggaggctgaggtgtggccgaggacctgac catctggaagtgtgaaaatccccttgggctgtcagaagccttgggcttggccataaatagggaggcagtggcacctctccatg ggggtggcgaaggtggaatgagaggatctacacagagtccccagcctgggctcaccctgcaccttctcttcccctctgacca cttttgcgcacgtcatccccgcagccaaggatgtcaaggccgctgctaatcagatgcgcaacttcctggttcgagcctcctgcc gccttcgcttggaacctgggaaagaatatttgatcatgggtctggatggggccacctatgacctcgagggacagtgagtcatct ggtcccctcagtctcttgtcctccccatgcctcgccacctaggccttgcccctcagaagccagatgcctgtgctctccgtttccac ctgccatcctcccgagccctgctgactgcccctttgccccctgcagcccccagtacctgctggactcgaatagctggatcgaggagatgccctctgaacgcctgtgccggagcacccgccagcgggcagcctgtgcccagctcaacgacttcctccaggagtat ggcactcaggggtgccaggtgtgagggctgccctcccacctccgctgggaggaacctgaacctgggaaccatgaagctgg aagcactgctgtgtccgctttcatgaacacagcctgggaccagggcatattaaaggcttttggcagcaaagtgtcagtgttggc agtgaagtgtcagtgtgtgttgctagggctgagagcagtgcccctgcccgatgcagttctgggcaggccaggttgacataacc ttagactctctgagccctgatgacccttgggctgttcagctctgctagaacctcccagatgacccgctaggagtctagtgcttca caggaccaccccgagcagaactgggacccaagagcctgcaccccaaggaccagagtccatgccaagaccacccttcagct tccaaggccctccactgcccggctgtcgccagtcaccacggcctcagacagggcttgtgctcagctgacacctgtgacacag ctcttctgcctcatgagctgttgtccagctacacctccccgactctgtcctcgtgctgctggcggttctgaggtctgcagattttag ctgagttccgggctgttgaaagcctgctgacgcttggttctgttatcagtggaatgaggtgactttcccggagttgtgcaatcctc aggtccggcagtgtcttcttccagttactggtttcaaacaagccaaaagtctgactttggtgtgtttgtgaatcctctgaggaagcc gctgttctcctggggtctccccttcccaccggacctgcctaactttcccccatttagtggcacacctggggtcttcagagatgactccgcgtctgtccaaagaagtttggtgagatcagtttccgtagaggtcatgacagttcagcagcctgccatccagtcattcgaca gaaattcgggaatctttcacttcatgccatgccctgtgccaggtgccagagatacagctgctcactccagggctcatcgctggg gagacagataagaggacgggcagtccccaccctctgtgaaagatgtgatgtcagggagcagtgtggtcctgtggggcatcta accaagtcaggggcattgccaggcagggacagggaaggcttcctggagcaggtggcctccaagtggggctctgaagactg agaaggagccaggaaaagagcaggggtagatgagggcatctggggcagaaggagaatatacaaaggcccagaggccgg gggcaggacagggtacctttggggacattgcatgtaattgaccacattcggagtttggatttggaagtggtggaagagatgga gatggtgagacaagtagtaagcacgtcagccttccaggtgcgctcctttccgatgagcactgtcttatcccacgtaactttgaga agtttgggcctttcccactgtggcagaggtttcctgaggctcttgcatacatggccctatggttgctcatcagatctttctcccagta gctgctcagcatggtggtggcataagcccattttccggagccagggattcagttgcagcaagacatggcccggtctgggagg tcaaccatgaagaaggcagtagctgtcattgcccaaccccagaaatcccaatcctgttttctccctctcagtcctgatcatggatt cagcagcagcgaactcgccaatgtagtgggtggcacagccagggtcttgactctggctctgcagtagcacagtctggaaaagctctgaggggagagagacccccactggtccgagggtctggcacagagccagaaatgggggggaaggtatggggctgggt cgcctctgacctctcaggtaccatccaggaggccctggcctctcactgaacccggccactcctctttggcatggcctcttccca aatccccaaactgcctccttacccacaaaagtggtctctgagtgtcagtccagtgggacccccaccccttatggcttcagttccc caaatagggctggacccttgatcctgatccagctgtggctatccagccccttcctggggactttggactttgaggggggcatgc ccagttgtgctgggaatccatactttccctggctggagtagaacctgtggactgtagtcctgagggcagtcatgttctgcctgtg cctggaaacacaagaaacttgactgcagagagaagaaagaggagagaggaacagagcgaggaaaccgcccgtctccgg ggctttttctgttccctatccttgactttctaagaccagtggggtcccctcctctgcttctttttcctgagttctgtgaaattccccaatt cttattttttatctcaaaccagctcaaggtgggctgttttcctttcaaccaaagaaaggtgctcctggtggctaaaggtacatattcg acagctagatttccaggctggaatcctgccctccacaacatgcgaacaatacccgtgttgcatatagagcatggctgtgaagag ttgagtgagtgcccacaaagcacttagagcagtgtctggtacatgctattactccgcagcgggaaaccacttcctcctttgtcttc tgggcacttttgtgagtgaaaggaggcactaataacaatcacactgggatacctgtatatactggaatgccccaggcaaaccaggcttaaactgtattactctatctgtagcttaaactaacaaacaacccacacaaatcacattttgttcttcaggcgattcaggaagg cctattaggcagggactgccattttctctctgagacaaacatcatgccagtaaactggcccacggtggggtggcagagggaga gggcccaggtgggggcggacactattgcctgcacagttgatgtggaaccagaaagctgactctggatgcaggaaaaaggtc agggttgcatttcccttccttgcttcttgatgggtgatcaatttttttgaaatacggacgtcccaaggccaatgagactggtgtcatt ccagaaaagggccactctgtgggcgggtcggtgggagggtacctgaaggtggggtcaagggaggccccaaaacagtcta cacagcaggagggatggctggggctcttgagctataagtggcacctcagggccctgacgggcgtctcgccatgctgctcctg ggcctgctgctgctgctgcccctgctggctggcgcccgcctgctgtggaactggtggaagctccggagcctccacctcccgc ctcttgccccgggcttcttgcacctgctgcagcccgacctccccatctatctgcttggcctgactcagaaattcgggcccatcta caggctccaccttgggctgcaaggtgagaggctgatctcgctctggccctcaccataggagggggcggaggtgacggaga gggtcctctctccgctgacgctgctttggctgtctcccagatgtggtggtgctgaactccaagaggaccattgaggaagccatg gtcaaaaagtgggcagactttgctggcagacctgagccacttacctgtaagggccgggggcattttttctttcttaaaaaaatttttttttaagagatgggttcttgctatgctgcccaggctggtcttaaattcctagtctcaaatgatcctcccacctcagcctcaagtgtga gccacctttggggcatccccaatccaggtccctggaagctcttgggggggcatatctggtggggagaaagcaggggttggg gaggccgaagaaggtcaggccctcagctgccttcatcagttcccaccctccagcccccacctcctcctgcagacaagctggt gtctaggaactacccggacctgtccttgggagactactccctgctctggaaagcccacaagaagctcacccgctcagccctgc tgctgggcatccgtgactccatggagccagtggtggagcagctgacccaggagttctgtgaggtaaggctgggctcctgagg ccacctcgggtcagcctcgcctctcacagtagcccccgccctgcccgctgcacagcggcctgctgaactcacactgtttctcc acagcgcatgagagcccagcccggcacccctgtggccattgaggaggaattctctctcctcacctgcagcatcatctgttacct caccttcggagacaagatcaaggtgcctcacagcccctcaggcccacccccagcccctccctgagcctctccttgtcctgaac tgaaagtactccctccttttctggcaggacgacaacttaatgcctgcctattacaaatgtatccaggaggtgttaaaaacctggag ccactggtccatccaaattgtggacgtgattccctttctcagggtgaggacctggagcctagacacccctgggttgtaggggag aggctggggtggagggagaggctccttcccacagctgcattctcatgcttcctgccgcagttcttccccaatccaggtctccggaggctgaagcaggccatagagaagagggatcacatcgtggagatgcagctgaggcagcacaaggtggggactgtacgtg gacggcctcccctcggcccacagccagtgatgctaccggcctcagcattgctatgaggcgggttcttttgcataccccagttat gggcctgttgccactctgtactcctctccccaggccagccgctcagcccgctcctttcaccctctgcaggagagcctcgtggca ggccagtggagggacatgatggactacatgctccaaggggtggcgcagccgagcatggaagagggctctggacagctcct ggaagggcacgtgcacatggctgcagtggacctcctgatcggtggcactgagaccacagcaaacaccctctcctgggccgt ggtttttttgcttcaccaccctgaggtgcgtcctggggacaagcaaaaggctccttcccagcaacctggccagggcggtgggc accctcactcagctctgagcactgtgcggctggggctgtgcttgcctcaccggcactcaggctcactgggttgctgagggagc ggctggaggctgggcagctgtgggctgctggggcaggactccacccgatcattccccagattcagcagcgactgcaggag gagctagaccacgaactgggccctggtgcctccagctcccgggtcccctacaaggaccgtgcacggctgcccttgctcaatg ccaccatcgccgaggtgctgcgcctgcggcccgttgtgcccttagccttgccccaccgcaccacacggcccagcaggtgac tcccgagggttggggatgagtgaggaaagcccgagcccagggaggtcctggccagcctctaactccagcccccttcagcat ctccggctacgacatccctgagggcacagtcatcattccgaacctccaaggcgcccacctggatgagacggtctgggagaggccacatgagttctggcctggtatgtggggggccgggggcctgccgtgaaaatgtggtggaggctggtccccgctgccgct gaacgcctccccacccacctgtccacccgcccgcagatcgcttcctggagccaggcaagaactccagagctctggccttcg gctgcggtgcccgcgtgtgcctgggcgagccgctggcgcgcctggagctcttcgtggtgctgacccgactgctgcaggcctt cacgctgctgccctccggggacgccctgccctccctgcagcccctgccccactgcagtgtcatcctcaagatgcagcctttcc aagtgcggctgcagccccgggggatgggggcccacagcccgggccagagccagtgatggggcaggaccgatgccagc cgggtacctcagtttctcctttattgctcccgtacgaacccctcccctcccccctgtaaacacagtgctgcgagatcgctggcag agaaggcttcctccagcggctgggtggtgaaggaccctggctcttctctcggggcgacccctcagtgctcggcagtcatactg gggtgcgagagaggtgggcagcagctcagcctccccccgctggggagcgaaagtttcttggtctcagcttcatttccgtgaa gggcaccgagaactcgaagcccttccagtggtaccagctcactccctgggaaaggggttgtcaagagagagtcaaagccgg atgtcccatctgctcttcccgttccccttaaggaggtagctcccagcactcaaccaacctccccgcagagctcccttcctgaccc tccgctgcagaggattgaggcttaattctgagctggccctttccagccaataaatcaactccagctccctctgcgaggctggcat gattgttccatttcacccagccactcagtcccttgcctgttacactgtggggctgaaacctaggcaggccgagccccagccaccccagctctgagccgcctccccacccctcacctgatggtccactgtgctcccgtagagcccgttgaggttggcgtagtggcagtt cctgtaccaccaggcccctcggtaggagacagcgcaggagatgagcaagctgttggggtcccgatcacgggcagagaaga cactgccgctgtggtagctcatggagtcccctgggcagggtggaggaaggagccatgagggcctcccctcccagcctcacc ctcccagcctcacagcctctgcttacctgcggtgccgtggtagccctccaagtggaggcggtagtactccgcagccgagtcta cgtggaaggagtcgtactgggcgaacacagcctcgtccccagcccgcaggtccacgcgcatggagtagtcacctgcctgtg tcaggctgtgcagggcctcattgcctgggggtgggatacgtgccctcatcagggtcctggtgtccacagggcccccatcccc atccgtagttccccagtccctgtgaggcactgacccagccagaactctccagagatgttcccaaaaccatgggcatagtcctcc cagtccctccagaagtctgtctgtccatccatgcggcgctggaacacctgggaagcaagtgggggcaccatcagcctctggc tcccggggcaacagaccctgccctgcacagacccctgggcttcccaatgccacccaccagccagccgcccccatcagtctc catgtcgcaaaacacgttcaggggccgctcgcggttgccgttgaggaagatggtgctggtcctggaggcaccggctccgttc tgcatctcctccccgcagtccctggggaaggggatccgcagcccacctgggagaggagagcaggggccagtccttttccaa gccttaggccctggctgcccacccagcccccggccccgggcccgtgcgtccaggtacccgtggtgaaagaggtggacacgggcggcaggaggctctggccccacatggcctggagccgtgcattgtaggaggtggagggaaagaggccaaggagctggt gagatgtgatccctcctgggagcaggatctcctgtgggacagacaagggggggtcaggggagagggaggtggagaccct ccgggagggccagaggcagcacctcctggaatcacccagggaggggagttgggtcagtggggccggggcacctggttct gtccaccaggggtgtggaagctgagcaggtagcctgcgggccggactgggggctcagtccaagtgagcagggcggtgcg gggggtcacttccttggcctccaagtcccgaggggcctctagccctaggagggaaagcaggaagaggagatggggatgag gcccaacctggctccctctacctcctctccctgtcccacacaccccacagaccctacctgtggtgaaggtgatgctggctggg gaagtgaggttggggccccgcaggccacgcactgtggcggtgtagttggtgtggaggacaaggtcatgcagggggtagtc caccgcgctgcctggggtctccgcctgcagaggcggggctgggagtgtagagaggggcatcaaggcctgccccctccatc ctcggccagagtccagcctcccccctgcaatccccaccctgaacaagtcccctccagaggcctcaggcctgctcacccccag gggctgtgacctggacgtcataggtgtccacaggattctgggggggcttccagtgcagcacggcgaatccctcggtcaagtt cagtgcacgcaactgtgtgggaccgtcaggaactgggggaaggggaggggctcagaagggtccccgcggctctctctact ccgtgcctccccagactccactggcctcccgtccgcaa< / INSDSeq_sequence>

[0217] < / insdseq>

[0218]

[0219] <sequencedata sequenceidnumber="4">

[0220] <insdseq>

[0221] <INSDSeq_length> 1485< / INSDSeq_length><INSDSeq_moltype> DNA< / INSDSeq_moltype><INSDSeq_division> PAT< / INSDSeq_division><INSDSeq_feature-table>

[0222] <insdfeature>

[0223] < INS DFeature_key > source < / IN S DFeature_key > <INSDFeature_location>1..1485< / INSDFeature_location> <INSDFeature_quals>

[0224] <insdqualifier>

[0225] <INSDQualifier_name>mol_type< / INSDQualifier_name>

[0226] <INSDQualifier_value>other DNA< / INSDQualifier_value>

[0227] < / insdqualifier>

[0228] <insdqualifier id="q9">

[0229] <INSDQualifier_name>organism< / INSDQualifier_name>

[0230] <INSDQualifier_value>synthetic construct< / INSDQualifier_value>< / insdqualifier>

[0231] < / INSDFeature_quals>

[0232] < / insdfeature> < / INSDSeq_feature-table>

[0233] <INSDSeq_sequence>atgctcttgctcggtctgttgttgttgctcccattgcttgcaggagcccgcctgttgt ggaactggtggaagctccggagcctgcatctcccccccttggcccctggctttcttcatcttttgcagcccgacctgcctatatat ctgctgggtctcactcagaagtttggacctatctaccgcctccacctggggctgcaggatgtggttgtgctcaattcaaaacgca caattgaggaggcgatggttaagaaatgggccgactttgccggaaggcctgaaccactgacatataagctcgttagccgcaat tacccagacctttccctgggcgattactccctgctctggaaagcccataagaagctcacacgatcagcactgctgctgggaatt cgcgacagcatggagcctgtcgtagaacagctgactcaggaattctgtgagcgcatgcgggcccaacctggcacacctgttg ccatcgaggaggagttttctttgcttacatgctccattatctgctacctcacattcggcgacaagattaaagacgacaatctgatgc ccgcctactacaagtgcatccaagaggtgctgaagacatggagtcactggagcatccaaatcgtcgatgtgatcccatttctga gattcttccccaaccccgggcttaggagacttaagcaggctatcgaaaagagggatcacatagtcgaaatgcaacttagacag cacaaagagtctctggtggccggccagtggcgcgacatgatggactatatgctgcagggcgtggctcagccatccatggaa gaaggcagcggacaactccttgaggggcatgttcatatggccgccgttgacttgctgattggcggaaccgaaacaactgctaatacactgtcctgggctgtggtattcctgctgcatcaccctgagatacagcaacggctccaagaggagctcgatcatgagctgg ggcccggtgcctcttcaagccgggtcccttacaaggaccgggcccgccttcctctgttgaatgcaaccatagctgaagtgctc agattgcgcccggtcgtaccactggccctccctcatagaaccaccaggcccagcagtatctccggatatgatatcccagagg ggactgtgattatcccaaacctgcagggcgcccatctggacgagactgtgtgggagcggccacatgaattctggcctgacag attcctcgagcctgggaagaactctcgggctctggcctttggttgcggggcaagggtatgcctgggggaacccttggcccgg ctggagcttttcgtagtgctgacacggctcctccaggcctttacgctgctgccaagcggcgacgctctgcctagcctgcaacca ctgcctcattgctcagtcattctcaaaatgcagccttttcaagtgaggctgcagccacgaggtatgggcgcacattctcctggcc agagccag< / INSDSeq_sequence>

[0234] < / insdseq>

[0235] < / sequencedata>

[0236] <sequencedata sequenceidnumber="5">

[0237] <insdseq>

[0238] <INSDSeq_length> 4101< / INSDSeq_length>

[0239] <INSDSeq_moltype> DNA< / INSDSeq_moltype>

[0240] <INSDSeq_division> PAT< / INSDSeq_division>

[0241] <INSDSeq_feature-table>

[0242] <insdfeature>

[0243] <INSDFeature_key>source< / INSDFeature_key>

[0244] <INSDFeature_location>1..4101< / INSDFeature_location>

[0245] <INSDFeature_quals>

[0246] <insdqualifier>

[0247] <INSDQualifier_name>mol_type< / INSDQualifier_name>

[0248] <INSDQualifier_value>other

[0249] DNA< / INSDQualifier_value>

[0250] < / insdqualifier>

[0251] <insdqualifier id="qll">

[0252] <INSDQualifier_name>organism< / INSDQualifier_name>

[0253] <INSDQualifier_value>synthetic construct< / INSDQualifier_value>

[0254] < / insdqualifier>

[0255] < / INSDFeature_quals>

[0256] < / insdfeature>

[0257] < / INSDSeq_feature-table>

[0258] <INSDSeq_sequence>gacaaaaaatactccatcggtctggacattggtactaactctgtaggct gggccgttatcacggacgagtagtacaaagtacctagcaaaaagttcaaagtttgggaatactgacaggcattccataaagaag aatctcataggagcattgctgtttgattccggagagacagcagaagctactgactcaagagaaccgcacgacgccgatatac acgccgaaaaaaccgaatctgctacctgcaggagatcttctccaatgaaatggctaaggtagacgacagcttctttcatcgactt ggaatctttctgttgaggaggataagaagcacgaacggcacctatttcggcaatatcgtggatgaggtcgcgtatcatg aaaagtatcccaccatctaccacttgcgaaagaagctggatagatagtaccgacaaggcggattgagactcatataccttgcac tggcccacatgataaaattcagagggcacttcctcatcgaaggtgatcttaatccagacaaacagtgacgtcgataagttgttcatt cagctcgtgcagacttacaatcaactgtttgaagaaaatcccataaatgcgtcaggcgtagatgcaaaggctatactctccgcg cgattgtcaaaatcccgacggcttgagaatctcatagcccaacttccccggcgaaaagaaaaacggattgttcgggaaccttatt gccttgtcactcggtttgactcctaattttaagagtaatttcgatctgggctgaggatgcaaaactgcagctgagtaagatacatac gacgacgacctggacaatctcctggcccagattggagaccagtacgccgacctgttcttggctgccaaaaaacctctcagacgctattctcctgtcagacattttgcgcgtgaatactgagattacgaaggcccccctgtctgcctccatgattaagcgctatgatgag caccatcaagacttgacccttcttaaagcgctggtacggcagcagctccctgaaaaatataaagaaatcttcttcgaccagtcca aaaatggctacgcgggctacatcgacggaggtgcaagccaggaggagttctataagtttataaagccgatccttgagaagatg gatgggaccgaagaactcctggtgaaacttaacagggaggatctgctgcgaaagcagcgcacatttgataatgggtccattcc acatcaaattcatcttggagaattgcacgccattttgagaagacaggaggacttctatccgtttcttaaggacaatcgggaaaaa atagaaaagatacttacattccgaattccttactatgtcgggcccttggcgcgagggaactctcggttcgcttggatgactcgaa aaagtgaggagactataactccttggaattttgaagaagtcgtagacaaaggtgcttccgcgcaatcttttatagagagaatgac taatttcgacaaaaacctcccaaacgagaaggttctgccaaagcacagccttctctacgagtattttactgtctataacgaactca ctaaggtgaaatacgtaactgaagggatgaggaagcctgcctttttgagtggcgagcagaagaaagcgatagtagatttgcttt ttaaaaccaaccggaaggtcactgtgaaacaacttaaagaagactacttcaagaagatagagtgtttcgacagcgtagaaatat ctggcgtagaggaccgcttcaatgcaagcttgggcacttaccatgacctcctcaagataatcaaagataaagattttcttgataatgaagagaatgaggatatccttgaagacatagtgttgactctcacgttgtttgaggatagggagatgatagaagagcgcttgaag acctatgctcatctcttcgatgataaagtaatgaagcaactcaagcggagaaggtatactggttggggtcggctttctaggaaac tcatcaacggtattcgggataaacagtccggcaaaactatattggatttccttaagagtgatggcttcgcgaaccgaaactttatg caacttatacatgatgattcacttacatttaaggaagacattcaaaaagcgcaagtatctggccagggcgactctctgcacgaac acatagcaaaccttgctggatcccctgcgataaagaaaggtatactgcagacagtaaaagttgtggacgaactcgtcaaggtta tgggtaggcataagcccgaaaatatagtgattgaaatggcacgcgagaaccaaactacacaaaaaggtcaaaagaacagca gagaacggatgaaacgaatagaggaggggatcaaggaacttggatcccaaatactgaaagagcaccccgtagaaaatacc cagcttcaaaacgagaagctttatctgtactacctgcaaaacggcagagatatgtacgtagaccaggaactggacatcaacag attgtctgattatgatgtagatcacattgtgccgcagagcttcctcaaagatgattccatagataacaaagtactcactcgaagtga caaaaacagagggaaatccgataatgttcccagtgaggaagtcgtcaagaagatgaagaattattggcggcaacttctcaacg cgaaactcatcacccaaagaaaattcgataacctcactaaagctgaacgcggaggactgtcagagcttgataaagcaggttttatcaaaaggcaactcgtagaaacgagacaaataacaaaacatgtcgctcaaattttggactctcgcatgaatacaaagtatgatg aaaatgacaaagctgattcgcgaggtcaaagtaataacgctcaaaagtaaacttgtctccgatttccgaaaggactttcagttttac aaagtcagagagataaataattaccaccacgcccatgacgcctacctcaatgctgtggttggtacggctcttatcaagaaatatc cgaagctcgagagcgagtttgtctatggcgactacaaggtttacgatgtcaggaaaatgatagcgaagtctgagcaagagata ggtaaggccacggctaaatactttttctattcaaatatcatgaattttttcaaaaccgagataacgttggcgaatggcgaaatcag gaaaaggcctcttatagagactaacggagaaacaggcgagattgtctgggataagggtagggatttcgctactgtgcgaaag gtactgagcatgccccaggttaacattgtcaaaaagactgaggtccaaacgggtggcttttctaaggagagtatcctgccaaaa cgcaattcagataagctcatagcgagaaaaaaggattgggaacccaaagaaatatggcggcttcgactctccgacggtcgcat atagtgtgctggtggttgccaaagttgaaaagggcaagtctaaaaaactgaaatcagtgaaggagcttctcggaataactattat ggagcgcagctcatttgaaaaaatccaatcgatttcttggaagcaaaaggatataaagaagtcaagaaggacctgatcatca aacttccaaagtactcactgttcgaacttgagaacggacggaagcggatgcttgcgagtgctggagaacttcaaaaaggtaacgagctcgcccttccatcaaagtacgtaaattttttgtacttggcatcacactatgagaagctcaaaggctcccccgaggataatg agcaaaagcagcttttcgtggaacaacataaacattaccttgatgaaatcatcgaacaaataagcgaattctctaaacgagttatt cttgcagacgcgaatctggacaaggtgcttagcgcatacaacaagcatcgggataagccgattcgagaacaagccgaaaata taatccatcttttcactctgacgaacttgggtgcgccggcagccttcaagtacttcgataccactattgataggaaacggtatacg agtacaaaagaagtgctggacgctacgcttatccatcagtccatcactgggctctacgagacgaggattgaccttagtcagttg ggcggggac< / INSDSeq_sequence>

[0259] < / insdseq> < / sequencedata>

[0260] < / inventorname> < / applicantnamelatin> < / applicantname>

Claims

CLAUSES OF THE INVENTION 1. An expression vector representing a viral particle of adeno-associated virus (AAV) having AAV capsid proteins, into which a single-stranded DNA molecule is packaged as a genome, at the ends of which are located the AAV ITR sequences, inside the AAV ITR the promoter of the first eukaryotic elongation factor EF1 alpha, the sequence of a histidine tag, the signal of intracellular localization in the nucleus 5'-SV40 NLS, the codon-optimized sequence of the Cas9 gene of Streptococcus pyogenes, another signal of intracellular localization in the nucleus 3'-SV40 NLS are located sequentially, and a synthetic polyA signal is used as a transcription terminator.

2. The expression vector according to I. 1, characterized in that the AAV ITR is the AAV serotype 2 ITR.

3. The expression vector according to claim 1, characterized in that the codon-optimized sequence of the Cas9 gene of Streptococcus pyogenes is SEQ ID N0:

5.

4. The expression vector according to item 1, characterized in that the vector is the sequence SEQ ID NO:

1.

5. An expression vector representing a viral particle of adeno-associated virus (AAV) having AAV capsid proteins, into which a single-stranded DNA molecule is packaged as a genome, at the ends of which are located the sequences of AAV ITR, inside the AAV ITR the eukaryotic promoter of polymerase III - U6 is located sequentially, after which the guide RNA expression cassette is located, including the sequence of the guide RNA in the crRNA format, complementary to the target locus, linked with the trackRNA sequence, the region of homology with the locus of the human genome AAVS1 - the left homologous arm, the expression cassette of the transgene: the EFS-NS promoter, under the control of which the protein-coding sequence of the hCYP21A2 gene is 78-99% identical to the sequence of SEQ ID N0: 3, the transcription terminator - polyA signal, the region of homology with the locus of the human genome AAVS1 - right homologous arm.

6. An expression vector according to I. 5, characterized in that the guide RNA sequence in crRNA format is a 20 nucleotide sequence.

7. The expression vector according to I. 5, characterized in that the AAV ITR is the AAV serotype 2 ITR.

8. An expression vector according to I. 5, characterized in that the polyA signal is the polyA signal of the human β-globin gene.

9. The expression vector according to item 5, characterized in that the vector is the sequence SEQ ID NO:

2.

10. A combination for the treatment of congenital adrenal cortex dysfunction, containing an expression vector for i. 1 and an expression vector for i.

5.

11. The combination according to claim 10, characterized in that it contains a pharmaceutically acceptable excipient.

12. The combination according to claim 11, characterized in that a buffer and / or physiological solution is used as a pharmaceutically acceptable excipient.

13. The combination according to item 11, characterized in that it is a pharmaceutical composition.

14. The combination according to claim 11, characterized in that it is a pharmaceutical composition.

15. A method for treating congenital adrenal cortex dysfunction, comprising administering to a mammal a combination of and. 10 in an effective amount.

16. A kit for producing proteins in mammalian cells, containing (i) expression vector according to i. 1, and (y) expression vector for i.

5.

17. The kit according to i.16, characterized in that the AAV ITR is an AAV serotype 2 ITR.

18. The kit according to I.16, characterized in that the codon-optimized sequence of the Cas9 gene of Streptococcus pyogenes is SEQ ID NO:

5.

19. The set according to I.16, characterized in that one of the said vectors is a vector with the sequence SEQ ID NO: 1 or SEQ ID NO:

2.

20. The set according to item 16, characterized in that one of the said vectors is a vector with the sequence SEQ ID NO: 1, and the second with the sequence SEQ ID NO:

2.

21. The kit according to claim 16, characterized in that the polyA signal is the polyA signal of the human β-globin gene.

22. The set according to I.16, characterized in that the sequence of the RNA guide in crRNA format is a sequence of 20 nucleotides.

23. The kit according to I.16, characterized in that it additionally contains a buffer and / or a physiological solution.

Citation Information

Patent Citations

  • Effective delivery of large genes by dual aav vectors

    EA034575B1

  • Delivery, construction and optimization of systems, methods and compositions for targeted action and modeling of diseases and disorders of postmitotic cells

    RU2725502C2

  • Induced caspases and methods for their use

    RU2757058C2

  • Novel crispr enzymes and systems

    RU2771826C9

  • Adeno-associated virus gene therapy for 21-hydroxylase deficiency

    WO2019143803A1